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Background: Hyperkalemia is one of the more serious complications of chronic
kidney disease (CKD), and the cause of potassium retention is a reduction in urinary
potassium excretion. However, few studies have examined the extent of the decrease
of urinary potassium excretion in detail with respect to decreased renal function.
Methods: Nine hundred eighty-nine patients with CKD (CKD stages G1 and G2
combined: 135; G3a: 107; G3b: 170; G4: 289; and G5: 288) were evaluated retro-
spectively. Values for urinary potassium excretion were compared between CKD
stages, and the associations between urinary potassium excretion and clinical pa-
rameters, including diabetes mellitus status and use of renineangiotensinealdosterone
system inhibitors, were analyzed using a multivariable linear regression analysis.
Results: Urinary potassium excretion gradually decreased with worsening of CKD
(G5: 24.8 ± 0.8 mEq/d, P < 0.001 vs. earlier CKD stages). In contrast, the value of
fractional excretion of potassium at CKD G5 was signiﬁcantly higher than that at the
other stages (30.63 ± 0.93%, P < 0.001). Multivariable linear regression analysis
revealed that urinary potassium excretion was independently associated with uri-
nary sodium excretion (standardized coefﬁcient, 0.499), the estimated glomerular
ﬁltration rate (0.281), and serum chloride concentration (e0.086).
Conclusion: This study demonstrated that urinary potassium excretion decreased
with reductions in renal function. Furthermore, urinary potassium excretion was
mainly affected by urinary sodium excretion and estimated glomerular ﬁltration
rate in patients with CKD, whereas the presence of diabetes mellitus and use of
renineangiotensinealdosterone system inhibitors were not associated with urinary
potassium excretion in this study.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ogy, First Department of
Jichi Medical University,
ma-ken 330-8503, Japan.
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Higher urinary potassium excretion was recently associated
with a lower risk of death and cardiovascular events and the
potential to reduce the incidence of hypertension in prospec-
tive cohort studies involving general populations [1,2]. There-
fore, urinary potassium excretion has been a concern in clinical
settings.y Elsevier. This is an open access article under the CC BY-NC-ND license
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experience potassium metabolism disorders, and the manage-
ment of which, particularly hyperkalemia, is one of the most
important aspects of CKD treatment. Urinary potassium
excretion is diminished in these patients [3,4], and several
mechanisms, including a reduction in functioning nephron
mass [5], use of a renineangiotensinealdosterone system
(RAAS) inhibitors [6], and the presence of diabetes mellitus
(DM) [7e10], are associated with this decrease. In contrast, to
avoid an increase in serum potassium concentrations associ-
ated with CKD, ampliﬁcation of the normal aldosterone-
induced signal for potassium excretion and an increase in po-
tassium excretion per nephron in accordance with the increase
in serum potassium concentrations have previously been re-
ported as part of the adaptation of renal potassium secretion in
patients with CKD [5,11]. However, few studies have examined
the extent of urinary potassium excretion in detail according to
CKD progression or the relationship between urinary potas-
sium excretion and clinical parameters in patients with CKD.
This study aimed to (1) compare the extent of urinary po-
tassium excretion between CKD stages [12] and (2) clarify the
relationship between urinary potassium excretion and clinical
parameters in patients with CKD.Methods
Patients and study design
This retrospective study included 989 patients (634 men and
355 women; mean age, 62.3 ± 0.5 years) who met the following
criteria: (1) the presence of CKD categorized into stages G1eG5
according to the CKD guidelines edited by the Japanese Society
of Nephrology [9] at the Division of Nephrology at Saitama
Medical Center in Jichi Medical University between January
2006 and December 2010; (2) completion of urinary electrolyte
measurements including potassium and sodium concentrations
via 24-hour urine collection; and (3) the absence of dialysis
treatment. This study was approved by the Institutional Review
Board of the Saitama Medical Center, Jichi Medical University
(RIN-13-30), Japan, and it conforms to the provisions of the
Declaration of Helsinki (as revised in Tokyo, 2004).
We collected and retrospectively analyzed sociodemo-
graphic patient data regarding age, sex, the presence of DM,
antihypertensive treatment with RAAS inhibitors including
angiotensin-converting enzyme inhibitors and angiotensin re-
ceptor blockers, and diuretic treatment with loop and thiazide
diuretics. Biochemical variables including blood urea nitrogen,
serum creatinine, sodium, potassium, chloride, albumin, and
hemoglobin levels were measured. We calculated the esti-
mated glomerular ﬁltration rate (eGFR) using the following
equation [12]:
eGFR

mL=min=1:73 m2

¼ 194 SCr1:094  age0:287 ðfor menÞ
¼ 194 SCr1:094  age0:287  0:739 ðfor womenÞ
where S-Cr indicates the serum creatinine concentration
(mg/dL).
Furthermore, 24-hour urine collection was performed for
each patient to evaluate urinary sodium, potassium, and protein
excretion. The 24-hour urine collection was initiated after theﬁrst morning urine was discarded in the patient's toilet. There-
after, the entire volume of urinewas collected in a disposable 3-L
container. To avoid the possibility of inadequate urine collection,
we trainedall patients to properly collect their urine samples and
reinforced that 24-hour urine collection must be initiated at a
speciﬁc time and then completed at the same time the next day.
On the basis of the results of these examinations, the frac-
tional excretion of potassium (FEK) was calculated using the
following equation:
FEK ð%Þ ¼ 100 ðUK=SKÞ=ðUCr=SCrÞ
where the U-K, S-K, U-Cr, and S-Cr indicates the urinary potassium
concentration (mEq/L), the serum potassium concentration (mEq/L),
the urinary creatinine concentration (mg/dL), and the serum
creatinine concentration (mg/dL), respectively.Statistical analysis
Data are expressed as means ± standard error. A chi-
square test was used to assess associations between categorical
variables, including the utilization and distribution of RAAS
inhibitors and diuretics, complemented by adjusted residual
analysis. Correlations between the 2 groups were evaluated
using the Pearson correlation coefﬁcient and linear regression
analysis, and differences between the 2 groups were evaluated
using the unpaired t test. The differences between CKD stages
were evaluated using a 1-way analysis of variance and the
Scheffe test. Variables that were signiﬁcantly correlated with
urinary potassium excretion in a simple linear regression
analysis, including the DM status and use of RAAS inhibitors,
were included in the multivariable linear regression analysis to
identify factors affecting urinary potassium excretion in pa-
tients with CKD. A P value < 0.05 was considered signiﬁcant.Results
Patient demographics and clinical characteristics are shown
in Table 1. The numbers of patients at each CKD stage were as
follows: G1 and G2 combined (G1 þ G2): 135; G3a: 107; G3b:
170; G4: 289; and G5: 288. The proportion of patients with DM
for CKD stages G4 and G5 signiﬁcantly increased compared to
CKD stages G1þ G2, G3a, and G3b (P < 0.05). The proportions of
patients using angiotensin-converting enzyme inhibitors and/or
angiotensin receptor blockers increased signiﬁcantly with
worsening of the CKD (P < 0.05, G3b vs. other stages). However,
there were no signiﬁcant differences between G4 and G5. The
proportion of patients using loop and/or thiazide diuretics and
polystyrene sulfonates also increased signiﬁcantly with CKD
progression (loop and/or thiazide diuretics: P < 0.05, G4 vs.
other stages; polystyrene sulfonates: P < 0.01, G1 þ G2 vs. G5).
Serum potassium concentrations at stage G5 were signiﬁcantly
higher than those at the earlier stages. Furthermore, the values
of urinary sodium excretion at stages G4 and G5 were signiﬁ-
cantly lower than those at CKD stages G1 þ G2, G3a, and G3b.
As shown in Fig. 1A, urinary potassium excretion did not
differ signiﬁcantly among stages G1 þ G2, G3a, and G3b;
however, the values were signiﬁcantly lower at G4 relative to
the earlier stages, and a further signiﬁcant decrease was
observed at G5 (G4: 33.9 ± 0.9 mEq/d, G5: 24.8 ± 0.8 mEq/d;
both P< 0.001 vs. earlier stages). In contrast, as shown in Fig.1B,
there was a signiﬁcant decrease in urinary potassium
Table 1. Comparison of patient characteristics according to CKD stages
CKD stage P
G1 þ G2 G3a G3b G4 G5
N 135 107 170 289 288
Woman/man 62/73* 36/71 62/108 87/202 108/180 *P ¼ 0.002 vs. G4
Age (y) 47.5 ± 1.5* 62.2 ± 1.3 63.8 ± 1.0 65.2 ± 0.8 65.4 ± 0.7 *<0.001 vs. other stages
With/without DM 20/115 27/80 44/126 109/180* 122/166** *<0.001 vs. G1 þ G2, P ¼ 0.028 vs. G3a,
P ¼ 0.013 vs. G3b
**< 0.001 vs. G1 þ G2 and G3b,
P ¼ 0.003 vs. G3a
With/without ACEI
and/or ARB,
use
53/82 (39.3)* 58/49 (49.5) 116/54 (68.2) 216/73 (74.7)* 220/68 (76.4)* *<0.001 vs. G1 þ G2 and G3a
With/without
diuretics, use
20/115 (14.8) 18/89 (16.8) 44/126 (25.9) 110/179 (38.1)* 176/112 (61.1)** *<0.001 vs. G1 þ G2 and G3a,
P ¼ 0.010 vs. G3b
**< 0.001 vs. G1 þ G2, G3a and G3b
With/without
polystyrene
sulfonates, use
0/135 (0) 4/103 (3.7) 7/163 (4.1) 17/272 (5.9)* 44/244 (15.3)** *P = 0.009 vs. G1 þ G2
**< 0.001 vs. G1 þ G2, G3b and G4,
P = 0.003 vs. G3a
eGFR (mL/min/
1.73 m2)
81.8 ± 1.5* 51.4 ± 0.4* 37.5 ± 0.3* 21.9 ± 0.3* 9.7 ± 0.3* *<0.001 vs. other stages
Serum sodium
(mEq/L)
140.0 ± 0.3 140.3 ± 0.3 140.6 ± 0.2 140.3 ± 0.2 139.0 ± 0.2* *<0.001 vs. G3b and G4, P ¼ 0.016 vs. G3a
Serum potassium
(mEq/L)
4.14 ± 0.04 4.32 ± 0.04 4.42 ± 0.03* 4.72 ± 0.04** 4.78 ± 0.04** *P ¼ 0.002 vs. G1 þ G2
** 0.001 vs. other stages
Serum chloride
(mEq/L)
104.5 ± 0.3 105.8 ± 0.3 106.1 ± 0.3 107.6 ± 0.2* 107.0 ± 0.3** *<0.001 vs. G1 þ G2, P ¼ 0.044 vs. G3b
**< 0.001 vs. G1 þ G2, P ¼ 0.002 vs. G3b
Urinary creatinine
excretion (g/d)
1.02 ± 0.03 1.03 ± 0.04 0.94 ± 0.02 0.89 ± 0.02* 0.78 ± 0.02** *P ¼ 0.004 vs. G1 þ G2, P ¼ 0.003 vs. G3a
**< 0.001 vs. G1 þ G2, G3a, and G3b,
P ¼ 0.003 vs. G4
Urinary sodium
excretion (mEq/d)
164.1 ± 6.3 157.0 ± 6.2 143.1 ± 4.7 132.3 ± 4.0* 121.8 ± 3.2* *<0.001 vs. G1 þ G2, G3a, G3b
Urinary protein
excretion (g/d)
0.90 ± 0.05 0.85 ± 0.04 0.88 ± 0.03 0.78 ± 0.02 0.74 ± 0.02* *P ¼ 0.021 vs. G1 þ G2, P ¼ 0.013 vs. G3b
Data are presented as mean ± SD or number (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; DM, diabetes mellitus;
eGFR, estimated glomerular ﬁltration rate.
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vs. G1 þ G2: P < 0.01; G3b vs. G3a: P < 0.05), before the sig-
niﬁcant decrease of urinary potassium excretion at G4. These
values were also signiﬁcantly decreased at stages G4 and G5
relative to earlier stages (G4: 20.7 ± 0.5 mEq/L; G5:
15.3± 0.3mEq/L, both P< 0.001 vs. earlier stages). Furthermore,
FEK values tended to increase according to the progression of
CKD, and the value at stage G5 was signiﬁcantly higher than
that at the other stages (G5: 30.63 ± 0.93%, P < 0.001; Fig. 2).
Table 2 shows the correlations between urinary potassium
excretion and the clinical parameters observed in the present
study. Urinary potassium excretion was positively correlated
with urinary sodium excretion and eGFR and negatively corre-
lated with age and serum chloride concentrations in a simple
linear regression analysis. However, there was no association
between urinary potassium excretion and serum potassium
concentrations. In addition, we performed a multivariable
linear regression analysis including variables that were signiﬁ-
cantly correlated with urinary potassium excretion in a simple
linear regression analysis, DM status, and the use of RAAS in-
hibitors. The multivariable regression analysis showed that
urinary potassiumexcretionwas independently associatedwith
urinary sodium excretion (standardized coefﬁcient, 0.499),
eGFR (0.281), and serum chloride concentration (e0.086),
whereas age, presence of DM, and use of RAAS inhibitors were
not signiﬁcantly and independently associated with urinary
potassium excretion in this study. Furthermore, we examined
the differences of urinary potassium excretion in patients with
or without DM and in those with or without the use of RAASinhibitors. As shown in Table 3, there were no differences of
urinary potassium excretion with or without DM and with or
without the use of RAAS inhibitors at each CKD stage.
Discussion
In this retrospective study involving patients with CKD, a
signiﬁcant decrease in urinary potassium excretion was
observed at CKD stage G4 relative to the earlier stages, and
this decrease progressed further at stage G5, ultimately
reaching approximately 25 mEq/d. Recently, the decrease of
urinary potassium excretion, which was less than 1.5 g/d, was
associated with an increased risk of death and cardiovascular
events in a large-scale epidemiologic cohort study [1]. Uri-
nary potassium excretion of 1.5 g/d corresponded to
38.4 mEq/d; therefore, the risk of death and cardiovascular
events may have been increased in patients with stage G4
and G5 CKD in this study because both values of urinary
potassium excretion were less than 38.4 mEq/d. However,
further study is required to clarify the relationship between
the level of urinary potassium excretion in patients with CKD
and their prognosis.
Concerning the decrease in urinary potassium excretion in
patients with CKD, several reports suggested that potassium
excretion ability is diminished because of reductions in renal
mass, administration of RAAS inhibitors, and the presence of
DM [3e10]. In the present study, in addition to the inﬂuence
of CKD progression on the decrease of urinary potassium
excretion, the previously reported relationship between
Figure 1. Urinary potassium excretion and concentrations. (A) Comparison of the levels of urinary potassium excretion among patients is shown at
different stages of CKD. (B) Comparison of urinary potassium concentrations is shown between CKD stages.
(A) *P < 0.001 vs. CKD G1 þ G2, G3a, and G3b.** P < 0.001 vs. CKD G1 þ G2, G3a, G3b, and G4. (B) *P < 0.01 vs. G1 þ G2 and P < 0.05 vs. G3a.**P < 0.001 vs.
G1 þ G2 and G3a and P < 0.01 vs. G3b.*** P < 0.001 vs. G1 þ G2, G3a, G3b, and G4.
CKD, chronic kidney disease.
Ueda et al / Urinary K excretion in CKD patients 81urinary potassium excretion and use of RAAS inhibitors was
believed to be present at CKD stages G1 þ G2eG4, to some
extent, because urinary potassium excretion decreased ac-
cording to increases in the use of RAAS inhibitors at these
stages. Furthermore, the proportions of patients with DM forFigure 2. Comparison of the fractional excretion of potassium among patie
*P < 0.001 vs. other CKD stages.
CKD, chronic kidney disease.CKD stages G4 and G5 were signiﬁcantly increased compared
to early CKD stages with the decrease of urinary potassium
excretion according to CKD progression. As to the relationship
between urinary potassium excretion and DM status, insulin
was reported to activate the basolateral Na/K pump andnts at different stages of CKD.
Table 3. Comparison of urinary potassium excretion in patients with or without DM and those with or without RAAS inhibitors
at each CKD stage
CKD stage
G1 þ G2 G3a G3b G4 G5
Urinary potassium excretion (mEq/d)
With DM 46.0 ± 3.1 40.8 ± 3.2 38.6 ± 2.2 38.8 ± 1.7 27.7 ± 1.3
Without DM 45.5 ± 1.7 47.3 ± 2.2 40.8 ± 1.5 31.5 ± 0.9 22.6 ± 1.0
P 0.966 0.558 0.791 0.164 0.136
Urinary potassium excretion (mEq/d)
With ACEI and/or ARB 45.2 ± 2.4 40.9 ± 2.0 40.4 ± 1.4 34.7 ± 1.1 24.7 ± 0.9
Without ACEI and/or ARB 45.8 ± 1.9 51.4 ± 3.0 39.3 ± 2.3 31.6 ± 1.6 25.1 ± 1.7
P 0.945 0.279 0.882 0.595 0.930
Data are presented as mean ± SD.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; DM, diabetes mellitus;
RAAS, renineangiotensinealdosterone system.
Table 2. Comparison between the variables included in the simple and multiple linear regression analyses of patients with CKD
vs. Urinary potassium excretion (mEq/d) Simple linear regression Multivariable linear regression
r P Standardized coefﬁcient P
Urinary sodium excretion (mEq/d) 0.564 < 0.001 0.499 < 0.0001
eGFR (mL/min/1.73 m2) 0.418 < 0.001 0.281 < 0.0001
Serum chloride (mEq/L) e0.167 < 0.001 e0.086 0.001
Age (y) e0.198 < 0.001 0.013 0.639
Urinary protein excretion (g/d) 0.186 0.567 e e
Serum sodium (mEq/L) 0.061 0.076 e e
Serum potassium (mEq/L) e0.042 0.281 e e
DM presence e e 0.031 0.214
ACEI and/or ARB use e e e0.023 0.371
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, esti-
mated glomerular ﬁltration rate.
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and enhance renal potassium secretion [13,14]. Therefore, the
presence of DM with insulin deﬁciency or insulin resistance
was expected to reduce urinary potassium excretion. How-
ever, according to the multivariable regression analysis and
the comparison of urinary potassium excretion in patients
with or without DM and in those with or without the use of
RAAS inhibitors at each CKD stage, neither the presence of
DM nor the use of RAAS inhibitors was associated with uri-
nary potassium excretion in this study. Regarding the inﬂu-
ence of DM and RAAS inhibitors on serum potassium
handling, previous investigations demonstrated that the
presence of DM, the use of RAAS inhibitors, and lowered
renal function or reduced eGFR are independent factors that
increase serum potassium level [15,16]. Therefore, factors
causing hyperkalemia would differ from those affecting uri-
nary potassium excretion in this study. To clarify urinary
potassium handling affected by clinical parameters, including
the presence of DM and use of RAAS inhibitors, further
studies will be required.
Diuretics such as loop diuretics and thiazides are known to
induce hypokalemia through an increase in urinary potassium
excretion [17]. In this study, although theproportions of patients
using diuretics were signiﬁcantly smaller at CKD stages
G1 þ G2eG3b, urinary potassium excretion ability decreased
signiﬁcantly according to the progression of CKD. Therefore, the
use of diuretics was not associated with urinary potassium
excretion because of the lack of a progressive increase in urinary
potassium excretion, evenwith an increase in the proportion of
patients using diuretics according to CKD progression.In this study, a signiﬁcant decrease in urinary potassium
concentration was revealed at CKD stage G3b before decreases
in urinary potassium excretion at CKD stage G4. In chronic renal
insufﬁciency, urine ﬂow in residual nephrons was adaptively
enhanced because of a decrease in tubular sodium reabsorption
[18], and this adaptive mechanism could contribute to the
preservation of urinary potassium excretion at CKD stage G3b,
even with a signiﬁcant decrease in the urinary potassium
concentration. Furthermore, we compared FEK values between
CKD stages. FEK values denote potassium excretion ability
corresponding to urinary creatinine excretion. In patients with
CKD, these values indicated a change in urinary potassium
excretion corresponding to a decrease in urinary creatinine
excretion. As the results illustrated, therewere no differences in
FEK values among CKD stages G1 þ G2 e G4; however, these
values increased signiﬁcantly at CKD stage G5 relative to those
observed at earlier stages. In patients with renal disease, FEK
values and creatinine clearance were signiﬁcantly and nega-
tively correlated [19]. According to previous ﬁndings and our
results, urinary potassium excretion ability would have been
maintained in each functioning nephron unit even in advanced
CKD stages, compared to the decrease in urinary creatinine
excretion.
Although a signiﬁcant positive relationship between plasma
potassium concentration and urinary potassium excretion has
been reported in chronic renal insufﬁciency [20], this was not
observed in this study. With respect to the correlation between
urinary potassium and sodium excretion, to stimulate urinary
potassium excretion, adequate sodium delivery to the distal
tubule and cortical collecting duct is necessary for aldosterone
Ueda et al / Urinary K excretion in CKD patients 83action [21]. In addition, the extent of tubular potassium
secretion in these segments, which accounts for most of the
total level of urinary potassium excretion, is determined by the
amount of sodium delivered to the nephrons [22]. Therefore,
the positive association between urinary potassium and so-
dium excretion in this study could be considered adequate,
which is consistent with previous reports. However, both uri-
nary potassium and sodium excretion usually decreased ac-
cording to the progression of CKD [3e5,23]. Therefore, it would
be difﬁcult to evaluate whether the positive correlation be-
tween urinary potassium and sodium excretion is a cause or
effect. Furthermore, there was a signiﬁcant independent cor-
relation between urinary potassium excretion and serum
chloride concentrations, although this correlation was
extremely weak. Because an increase of the serum chloride
concentration, which is sometimes associated with hyper-
chloremic metabolic acidosis, frequently appears according to
the progression of CKD, this association might reﬂect the result
accompanying the progression of CKD.
Regarding the limitations of this study, because serum
aldosterone concentrations were not measured, we cannot
comment on whether urinary potassium excretion was inﬂu-
enced by the action of aldosterone in patients with CKD.
Moreover, the proportion of patients receiving dietary educa-
tion, including salt and potassium restrictions (salt intake of
less than 6 g/d and potassium intake of less than 40 mEq/d),
was considered to increase according to the progression of CKD.
Therefore, the inﬂuence of potassium restriction cannot be
excluded from the decreases in urinary potassium excretion
and concentrations although serum potassium concentrations
increased with worsening of CKD.
In conclusion, this study demonstrated that urinary potas-
sium excretion decreased according to reductions in renal
function. Furthermore, urinary potassium excretionwasmainly
affected by urinary sodium excretion and eGFR in patients with
CKD, whereas the presence of DM and use of RAAS inhibitors
were not associated with urinary potassium excretion in this
study.
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